Impact of cotransplantation of mesenchymal stem cells on lung function after unrelated allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning

Transplantation

Volumn 98, Issue 3, 2014, Pages 348-353

  Moermans, Catherine ^a   Lechanteur, Chantal ^b   Baudoux, Etienne ^b   Giet, Olivier ^b   Henket, Monique ^a   Seidel, Laurence ^a   Lejeune, Marie ^a   Willems, Evelyne ^a   Baron, Frederic ^a   Louis, Renaud ^a   Beguin, Yves ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Exhaled nitric oxide; Lung function; MSC; Stem cell transplantation

Indexed keywords

NITRIC OXIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; EXHALED NITRIC OXIDE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; LUNG DIFFUSION CAPACITY; LUNG INFECTION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MYCOSIS; NEUTROPENIA; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESIDUAL VOLUME; RESPIRATORY TRACT INFLAMMATION; RESPIRATORY TRACT PARAMETERS; TOTAL LUNG CAPACITY; UNRELATED DONORS; VIRUS INFECTION; VIRUS REACTIVATION;

ADULT; AGED; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LUNG; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 84905819811     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000068     Document Type: Article

References (42)

1. Baron F, Lechanteur C, Willems E, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 2010; 16: 838.
2. von Bahr L, Sundberg B, Lonnies L, et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012; 18: 557.
3. Bernardo ME, Cometa AM, Locatelli F. Mesenchymal stromal cells: A novel and effective strategy for facilitating engraftment and accelerating hematopoietic recovery after transplantation Bone Marrow Transplant 2012; 47: 323.
4. Lin Y, Hogan WJ. Clinical application of mesenchymal stem cells in the treatment and prevention of graft-versus-host disease. Adv Hematol 2011; 2011: 427863.
5. Sundin M, Barrett AJ, Ringden O, et al. HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother 2009; 32: 755.
6. Schrepfer S, Deuse T, Reichenspurner H, et al. Stem cell transplantation: The lung barrier. Transplant Proc 2007; 39: 573.
7. Aguilar S, Nye E, Chan J, et al. Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells 2007; 25: 1586.
8. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102: 3837.
9. Yan X, Liu Y, Han Q, et al. Injured microenvironment directly guides the differentiation of engrafted Flk-1(+) mesenchymal stem cell in lung. Exp Hematol 2007; 35: 1466.
10. Salazar KD, Lankford SM, Brody AR. Mesenchymal stem cells produce Wnt isoforms and TGF-beta1 that mediate proliferation and procollagen expression by lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2009; 297: L1002.
11. Gupta N, Su X, Popov B, et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007; 179: 1855.
12. Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005; 33: 145.
13. Jungebluth P, Luedde M, Ferrer E, et al. Mesenchymal stem cells restore lung function by recruiting resident and nonresident proteins. Cell Transplant 2011; 20: 1561.
14. Iyer SS, Co C, Rojas M. Mesenchymal stem cells and inflammatory lung diseases. Panminerva Med 2009; 51: 5.
15. Chien JW, Madtes DK, Clark JG. Pulmonary function testing prior to hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 35: 429.
16. Beeh KM, Kornmann O, Lill J, et al. Induced sputum cell profiles in lung transplant recipients with or without chronic rejection: Correlation with lung function. Thorax 2001; 56: 557.
17. Travers J, Marsh S, Aldington S, et al. Reference ranges for exhaled nitric oxide derived from a random community survey of adults. Am J Respir Crit Care Med 2007; 176: 238.
18. Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graftversus-host disease according to National Institutes of Health consensus criteria. Blood 2011; 117: 3214.
19. Nichols WG, Corey L, Gooley T, et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273.
20. Fukuda T, Boeckh M, Guthrie KA, et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004; 10: 494.
21. Bagaitkar J, Demuth DR, Scott DA. Tobacco use increases susceptibility to bacterial infection. Tob Induc Dis 2008; 4: 12.
22. Donowitz GR, Maki DG, Crnich CJ, et al. Infections in the neutropenic patientVnew views of an old problem. Hematology Am Soc Hematol Educ Program 2001; 39: 113.
23. Blennow O, Remberger M, Klingspor L, et al. Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant 2010; 45: 1710.
24. Lee JW, Krasnodembskaya A, McKenna DH, et al. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 2013; 187: 751.
25. Meisel R, Brockers S, Heseler K, et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 2011; 25: 648.
26. Krasnodembskaya A, Song Y, Fang X, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010; 28: 2229.
27. Auletta JJ, Deans RJ, Bartholomew AM. Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. Blood 2012; 119: 1801.
28. Forslow U, Blennow O, LeBlanc K, et al. Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2012; 89: 220.
29. Remberger M, Ringden O. Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: A comparison with non-MSC treated patients. Int J Hematol 2012; 96: 822.
30. Lucchini G, Dander E, Pavan F, et al. Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation. Stem Cells Int 2012; 2012: 690236.
31. George B, Pati N, Gilroy N, et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stemcell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 2010; 12: 322.
32. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008; 371: 1579.
33. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993.
34. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756.
35. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945.
36. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the singlebreath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26: 720.
37. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J 2005; 26: 153.
38. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26: 511.
39. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005; 171: 912.
40. Castermans E, Baron F, Willems E, et al. Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning. Haematologica 2008; 93: 240.
41. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695.
42. Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007; 110: 2744.